Opus Genetics is trading at $3.99 (7.6% up) in pre-market with no clear catalyst yet, rebounding after closing at $3.71 on August 04.
- Recent news flow remains quiet with no fresh earnings, FDA updates, M&A, or major analyst actions reported overnight to explain the move.
- The stock’s advance comes against a slightly positive broader U.S. equity backdrop, suggesting the strength may reflect general risk-on sentiment rather than company-specific developments.